Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spyre Therapeutics ( (SYRE) ) just unveiled an update.
On May 29, 2025, Spyre Therapeutics, Inc. held its Annual Meeting of Stockholders where three Class III directors were elected, executive compensation was approved on an advisory basis, and KPMG LLP was ratified as the independent registered public accounting firm for 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (SYRE) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
Spyre Therapeutics is facing significant financial challenges with consistent revenue and profitability issues. Its strong equity position is overshadowed by operational cash flow problems and persistent losses. Technically, the stock is under bearish pressure, and the valuation is complicated by a negative P/E ratio and lack of dividends. These factors combined result in a low overall stock score, reflecting the high-risk nature of investing in this biotechnology company.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Average Trading Volume: 659,816
Technical Sentiment Signal: Sell
Current Market Cap: $922.2M
For a thorough assessment of SYRE stock, go to TipRanks’ Stock Analysis page.